Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $1.72 billion. The enterprise value is $1.12 billion.
Important Dates
The last earnings date was Monday, November 10, 2025, after market close.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 66.45 million shares outstanding. The number of shares has increased by 9.16% in one year.
| Current Share Class | 66.45M |
| Shares Outstanding | 66.45M |
| Shares Change (YoY) | +9.16% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 95.22% |
| Float | 56.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 656.06 |
| Forward PS | 483.99 |
| PB Ratio | 2.89 |
| P/TBV Ratio | 2.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 432.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.01, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.01 |
| Quick Ratio | 12.55 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.44% and return on invested capital (ROIC) is -23.04%.
| Return on Equity (ROE) | -32.44% |
| Return on Assets (ROA) | -21.77% |
| Return on Invested Capital (ROIC) | -23.04% |
| Return on Capital Employed (ROCE) | -42.57% |
| Revenue Per Employee | $13,973 |
| Profits Per Employee | -$1.21M |
| Employee Count | 186 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.64% in the last 52 weeks. The beta is 1.13, so CLDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +9.64% |
| 50-Day Moving Average | 25.64 |
| 200-Day Moving Average | 22.08 |
| Relative Strength Index (RSI) | 53.64 |
| Average Volume (20 Days) | 888,288 |
Short Selling Information
The latest short interest is 7.51 million, so 11.30% of the outstanding shares have been sold short.
| Short Interest | 7.51M |
| Short Previous Month | 7.40M |
| Short % of Shares Out | 11.30% |
| Short % of Float | 13.35% |
| Short Ratio (days to cover) | 8.76 |
Income Statement
In the last 12 months, CLDX had revenue of $2.60 million and -$224.53 million in losses. Loss per share was -$3.38.
| Revenue | 2.60M |
| Gross Profit | -214.08M |
| Operating Income | -256.24M |
| Pretax Income | -224.53M |
| Net Income | -224.53M |
| EBITDA | -252.86M |
| EBIT | -256.24M |
| Loss Per Share | -$3.38 |
Full Income StatementBalance Sheet
The company has $583.22 million in cash and $2.62 million in debt, giving a net cash position of $580.60 million or $8.74 per share.
| Cash & Cash Equivalents | 583.22M |
| Total Debt | 2.62M |
| Net Cash | 580.60M |
| Net Cash Per Share | $8.74 |
| Equity (Book Value) | 598.36M |
| Book Value Per Share | 9.01 |
| Working Capital | 557.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$179.48 million and capital expenditures -$2.19 million, giving a free cash flow of -$181.67 million.
| Operating Cash Flow | -179.48M |
| Capital Expenditures | -2.19M |
| Free Cash Flow | -181.67M |
| FCF Per Share | -$2.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -9,859.22% |
| Pretax Margin | -8,639.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.16% |
| Shareholder Yield | -9.16% |
| Earnings Yield | -13.17% |
| FCF Yield | -10.65% |
Dividend DetailsAnalyst Forecast
The average price target for CLDX is $43.80, which is 69.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.80 |
| Price Target Difference | 69.24% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 144.23% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 14.34 and a Piotroski F-Score of 1.
| Altman Z-Score | 14.34 |
| Piotroski F-Score | 1 |
